Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter

British Journal of Pharmacology

Volumn 168, Issue 7, 2013, Pages 1750-1757

  Cameron, Krasnodara N ^a   Kolanos, Renata ^b   Solis, Ernesto ^a   Glennon, Richard A ^b   De Felice, Louis J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

also 4 methylmethcathinone or MMC); bath salts; cocaine; dopamine transporter; mephedrone (MEPH; methamphetamine; methylenedioxypyrovalerone (MDPV); synthetic cathinones

Indexed keywords

3,4 METHYLENEDIOXYPYROVALERONE; 4' METHYLMETHCATHINONE; BATH SALT; CATHINONE; COCAINE; DOPAMINE TRANSPORTER; METHAMPHETAMINE; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MEMBRANE DEPOLARIZATION; CHEMICAL COMPOSITION; CHEMICAL INTERACTION; CONTROLLED STUDY; DOPAMINE RELEASE; EXCITATORY JUNCTION POTENTIAL; FEMALE; HUMAN; HYPERPOLARIZATION; IC 50; MEMBRANE STEADY POTENTIAL; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; XENOPUS LAEVIS;

EID: 84875206459     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12061     Document Type: Article

References (40)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to receptors and channels, 5th edn. Br J Pharmacol 164: 1-324.
2. Banks ML, Blough BE, Negus SS, (2011). Effects of monoamine releasers with varying selectivity for releasing dopamine/norepinephrine versus serotonin on choice between cocaine and food in rhesus monkeys. Behav Pharmacol 22: 824-836.
3. Baumann MH, Ayestas MAJ, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al,. (2012). The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37: 1192-1203.
4. Bruns D, Engert F, Lux HD, (1993). A fast activating presynaptic reuptake current during serotonergic transmission in identified neurons of Hirudo. Neuron 10: 559-572.
5. Carvelli L, Blakely RD, DeFelice LJ, (2008). Dopamine transporter/syntaxin 1A interactions regulate transporter channel activity and dopaminergic synaptic transmission. Proc Natl Acad Sci U S A 105: 14192-14197.
6. Coppola M, Mondola R, (2012). 3,4-Methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett 208: 12-15.
7. Drug Enforcement (2011). Schedules of controlled substances: temporary placement of three synthetic cathinones into schedule I. In:, Department J, (ed.). Federal Register, Vol. 76. Government Printing Office: Washington, DC, pp. 65371-65375.
8. Glennon RA, (1993). Cathinone. Available at: http://www.pharmacy.vcu.edu/ medchem/articles/cat/cat.html (accessed 30/6/2012).
9. Glennon RA, Showalter D, (1981). The effect of cathinone and several related derivatives on locomotor activity. Res Commun Subst Abuse 2: 186-192.
10. Glennon RA, Yousif M, Naiman N, Kalix P, (1987). Methcathinone: a new and potent amphetamine-like agent. Pharmacol Biochem Behav 26: 547-551.
11. Guptaroy B, Fraser R, Desai A, Zhang M, Gnegy ME, (2011). Site-directed mutations near transmembrane domain 1 alter conformation and function of norepinephrine and dopamine transporters. Mol Pharmacol 79: 520-532.
12. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, et al,. (2011). 4-Methyl-methcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339: 530-536.
13. Han DD, Gu HH, (2006). Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacology 6: 1-7.
14. Howell LL, Kimmel HL, (2007). Psychostimulants. In:, Sibley DR, Hanin I, Kuhar M, Skolnick P, (eds). Handbook of Contemporary Neuropharmacology, Vol. 2. John Wiley & Sons: Hoboken, NJ, pp. 567-611.
15. Howell LL, Carroll FI, Votaw JR, Goodman MM, Kimmel HL, (2007). Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration in rhesus monkeys. J Pharmacol Exp Ther 320: 757-765.
16. Huang P-K, Aarde SM, Angrish D, Houseknecht KL, Dickerson TJ, Taffe MA, (2012). Contrasting effects of d-methamphetamine, 3,4- methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats. Drug Alcohol Depend 126: 168-175.
17. Ingram SL, Prasad BM, Amara SG, (2002). Dopamine transporter-mediated conductances increase excitability of midbrain dopamine neurons. Nat Neurosci 5: 971-978.
18. Iversen L, (2010). Consideration of the cathinones, Advisory Council on the Misuse of Drugs (ACMD). Available at: http://www.homeoffice.gov.uk/ publications/agencies-public-bodies/acmd1/acmd-cathinodes-report-2010 (accessed 30/6/2012).
19. Iwamoto H, Blakely RD, DeFelice LJ, (2006). Na+, Cl-, and pH dependence of the human choline transporter (hCHT) in xenopus oocytes: the proton inactivation hypothesis of hCHT in synaptic vesicles. J Neuroscience 26: 9851-9859.
20. Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, et al,. (2005). Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci U S A 102: 3495-3500.
21. Kalix PG, (1986). Further evidence for an amphetamine-like mechanism of action of the alkaloid cathinone. Biochem Pharmacol 35: 3015-3019.
22. Kalix PG, (1992). Cathinone, a natural amphetamine. Pharmacol Toxicol 70: 77-86.
23. Kehr J, Ichinose F, Yoshitake S, et al,. (2011). Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol 164: 1949-1958.
24. Kelly JP, (2011). Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal 3: 439-453.
25. Lõpez-Arnau R, Martínez-Clemente J, Pubill D, Escubedo E, Camarasa J, (2012). Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone. Br J Pharmacol 167: 407-420.
26. Machaca K, Hartzell H, (1998). Asymmetric distribution of Ca-activated Cl channels in xenopus oocytes. Biophysical J 74: 1286-1295.
27. Martínez-Clemente J, Escubedo E, Pubill D, Camarasa J, (2012). Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol 22: 231-236.
28. Meltzer PC, Butler D, Deschamps JR, Madras BK, (2006). 1-(4-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogs. A promising class of monoamine uptake inhibitors. J Med Chem 49: 1420-1432.
29. Motbey CP, Hunt GE, Bowen MT, Artiss S, McGregorIain S, (2011). Mephedrone (4-methylmethcathinone,'meow'): acute behavioural effects and distribution of Fos expression in adolescent rats. Addict Biol 17: 409-422.
30. Negus SS, Mello NK, Blough BE, Baumann MH, Rothman RB, (2007). Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate 'agonist' medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys. J Pharmacol Exp Ther 320: 627-636.
31. Rodriguez-Menchaca AA, Solis J, Solls E Jr, Cameron K, De Felice LJ, (2011). S(+)Amphetamine Induces a persistent leak in the human dopamine Transporter: molecular stent hypothesis. Br J Pharmocol 165: 2749-2757.
32. Rothman RB, Baumann MH, (2006). Therapeutic potential of monoamine transporter substrates. Curr Top Med Chem 6: 1845-1859.
33. Sellings LH, Clarke PB, (2003). Segregation of amphetamine reward and locomotor stimulation between nucleus accumbens medial shell and core. J Neurosci 23: 6295-6303.
34. Simmler L, Buser T, Donzelli M, Schramm Y, Dieu L-H HJ, et al,. (2012). Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168: 458-470.
35. Sonders MS, Zhu SJ, Zahniser NR, Kavanaugh MP, Amara SG, (1997). Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J Neurosci 17: 960-974.
36. Spiller H, Ryan M, Weston R, Jansen J, (2011). Clinical experience with and analytical confirmation of 'bath salts' and 'legal highs' (synthetic cathinones) in the United States. Clin Toxicol 49: 499-505.
37. Sulzer D, (2012). How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron 69: 628-649.
38. Sulzer D, Sonders MS, Poulsen NW, Galli A, (2005). Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75: 406-433.
39. Symposium BS, (2012). CPDD annual meeting. Available at: http://www.cpddblog.com/2012/06/bath-salts-symposium-at-2012-cpdd.html (accessed 30/6/2012).
40. Williams JM, Galli A, (2006). The dopamine transporter: a vigilant border control for psychostimulant action. Handb Exp Pharmacol 175: 215-232.